The authors wish to indicate that the description of the biomarker assays in the methods section is not correct. Galectin-3 and ST2 were not measured using the BG Medicine assay and the Presage assay (Critical Diagnostics), which both have been cleared for clinical use. Instead, the reported values of galectin-3 and ST2 were measured using enzyme-linked immunosorbent assays (ELISAs) on a Luminex platform from Alere, Inc. (San Diego, CA, USA) that has not been cleared for clinical use. The authors regret the error.